The Yasmin birth control lawsuit refers to a massive wave of litigation against Bayer Pharmaceuticals in which over 19,000 lawsuits were filed by women who alleged that Yaz and Yasmin birth control pills caused serious injuries including blood clots, heart attacks, strokes, gallbladder complications, and deaths. In the United States, Bayer ultimately paid more than $2 billion in settlements to resolve the bulk of these claims, making it one of the largest pharmaceutical settlements in history. The litigation was consolidated as a multidistrict litigation (MDL No. 2100) in the Southern District of Illinois beginning in October 2009 and officially closed on January 4, 2019. While U.S.
law firms are no longer accepting new Yaz or Yasmin claims, a separate Canadian class action remains active heading into 2026. A settlement agreement was signed on July 30, 2025, creating a proposed CAD $9,050,000 settlement fund, with courts in Ontario and Québec approving the deal in late November 2025. Saskatchewan’s hearing was rescheduled to February 11, 2026, and all three provincial courts must sign off before the settlement can proceed. This article covers the health risks at the center of the litigation, how the U.S. settlements broke down, where the Canadian class action stands today, and what affected individuals should know.
Table of Contents
- What Were the Yasmin Birth Control Lawsuits About?
- How Did the $2 Billion in U.S. Settlements Break Down?
- The Canadian Class Action — What Is Happening in 2026?
- Can You Still File a Yasmin or Yaz Lawsuit?
- Health Risks of Drospirenone — What the FDA Warned About
- Bayer’s Legal Strategy and the No-Fault Settlement Approach
- What the Yasmin Litigation Means Going Forward
- Conclusion
What Were the Yasmin Birth Control Lawsuits About?
At the heart of every Yasmin and yaz lawsuit was a synthetic progestin called drospirenone, which distinguishes these oral contraceptives from older formulations. Both pills combine drospirenone with ethinyl estradiol, a common synthetic estrogen. The FDA has warned that drospirenone can increase potassium levels in the blood, a condition that can become dangerous and contribute to cardiovascular events. Plaintiffs alleged that Bayer failed to adequately warn consumers and the medical community about the elevated risks associated with drospirenone compared to other progestins on the market. The injuries alleged in these lawsuits were severe. Women reported developing deep vein thrombosis, where blood clots form in the legs, as well as pulmonary embolism, where those clots travel to the lungs.
Others suffered heart attacks and strokes, sometimes at unusually young ages. A significant number of claimants also experienced gallbladder disease requiring surgery. In the most tragic cases, families filed wrongful death claims after women died from complications attributed to these medications. For many plaintiffs, what had been a routine contraceptive decision turned into a life-altering medical crisis. Bayer, for its part, has not admitted liability or fault in any of the settlements. The company continues to maintain that the evidence supports the safety and efficacy of Yaz and Yasmin when used as directed. This is a standard posture in pharmaceutical litigation, where companies often settle to avoid the unpredictability of jury trials while publicly standing behind their products.
How Did the $2 Billion in U.S. Settlements Break Down?
The total U.S. settlements exceeded $2 billion, but the payouts were not distributed evenly across injury categories. The vast majority of the money, approximately $2.04 billion, went to settle roughly 10,300 claims involving blood-clot injuries such as deep vein thrombosis and pulmonary embolism. These were the most common and often the most medically serious injuries alleged. An additional $56.9 million resolved around 1,200 claims for strokes and heart attacks, while $21.5 million settled approximately 7,200 claims related to gallbladder injuries. On average, settlements worked out to approximately $218,000 per case, though individual amounts varied widely based on the severity of injury, strength of evidence, and other factors. It is worth noting that the per-case average of $218,000 is just that, an average.
Women who suffered permanent disability or required extended hospitalization likely received significantly more, while those with less severe outcomes may have received less. Settlement negotiations in mass torts like this often create tiered structures where compensation scales with the documented harm. However, if a claimant had pre-existing conditions that could independently explain her injuries, her settlement value may have been reduced or her claim denied altogether. The causal link between the drug and the specific injury remained a central point of contention throughout the litigation. The sheer scale of the payouts, exceeding $2 billion, placed the Yaz and Yasmin litigation among the most expensive pharmaceutical settlements in U.S. history. For context, the total exceeded what many companies earn in annual revenue, underscoring just how widespread the alleged harm was.
The Canadian Class Action — What Is Happening in 2026?
While the U.S. litigation has been fully resolved and closed since January 2019, a parallel class action in Canada has followed its own timeline. A settlement agreement was signed on July 30, 2025, covering class actions filed across multiple Canadian provinces. The proposed settlement creates a CAD $9,050,000 fund intended to cover notice and administration costs, provincial health insurer claims, legal fees, and benefits for individual claimants. Courts in Ontario and Québec approved the settlement on November 26 and 27, 2025, respectively, following hearings held on November 14, 2025. However, the Saskatchewan hearing was rescheduled to February 11, 2026, and all three provincial courts must approve the settlement before it can take effect.
As of early 2026, the claims process has not yet begun, and no money is currently available for class members. This is a critical detail for Canadian residents who may have been affected: even though a settlement has been negotiated, it is not yet final, and there is no mechanism to file a claim or receive compensation at this time. The Canadian settlement fund of CAD $9,050,000 is dramatically smaller than the U.S. payouts, reflecting differences in the size of the Canadian market, the number of claimants, and the structure of the Canadian legal system. Canadian class actions typically operate under different procedural rules than U.S. multidistrict litigation, and individual payouts in Canadian pharmaceutical class actions tend to be lower.
Can You Still File a Yasmin or Yaz Lawsuit?
For anyone in the United States considering legal action over Yaz or Yasmin, the window has closed. U.S. law firms are no longer accepting new claims related to these contraceptives. The MDL was consolidated in 2009, settlements were negotiated over several years, and the case was officially closed in January 2019. Statutes of limitations have long since expired for most potential claimants, and there is no active litigation infrastructure to process new cases. In Canada, the situation is different but still limited.
While the class action is active and a settlement has been proposed, the claims process has not yet opened. Canadian residents who believe they were harmed by Yaz or Yasmin should monitor updates from the law firms involved in the class action, including Siskinds Desmeules and McKenzie Lake, for announcements about when and how to submit claims. The tradeoff for Canadian claimants is that while they still have a path to compensation, the total fund is relatively modest, and individual payouts after legal fees, administration costs, and health insurer claims are deducted may be limited. The contrast between the two countries illustrates a broader pattern in cross-border pharmaceutical litigation. U.S. cases tend to resolve faster and with larger payouts due to the availability of jury trials, punitive damages, and contingency-fee attorneys who aggressively pursue mass tort claims. Canadian class actions, while providing broader class-wide coverage, often result in smaller individual recoveries.
Health Risks of Drospirenone — What the FDA Warned About
The FDA’s warnings about drospirenone were central to the litigation. Drospirenone is a progestin with anti-mineralocorticoid properties, meaning it affects how the body handles potassium. In some women, particularly those taking other medications that raise potassium levels (such as ACE inhibitors, potassium-sparing diuretics, or NSAIDs), drospirenone can push potassium to dangerously high levels. Elevated potassium, known as hyperkalemia, can cause irregular heartbeats and, in severe cases, cardiac arrest. Beyond the potassium issue, studies examined whether drospirenone-containing contraceptives carried a higher risk of venous thromboembolism compared to older progestins like levonorgestrel.
Several epidemiological studies suggested an elevated risk, though the absolute risk remained low for any individual user. This is an important limitation to understand: most women who take Yaz or Yasmin will not experience serious side effects. The lawsuits focused on those who did suffer harm and argued that Bayer should have done more to warn both doctors and patients about the comparative risks. Women currently taking drospirenone-containing contraceptives should not panic, but they should have an informed conversation with their healthcare provider about their individual risk factors. Those with a personal or family history of blood clots, cardiovascular disease, or conditions that affect potassium levels should be particularly cautious.
Bayer’s Legal Strategy and the No-Fault Settlement Approach
Bayer’s decision to settle over 19,000 lawsuits without admitting fault is not unusual in pharmaceutical mass tort litigation. Companies routinely calculate that the cost of settling, even for billions of dollars, is preferable to the risk of sympathetic juries awarding unpredictable damages in individual trials. Early bellwether trials in the Yaz MDL produced mixed results, with some verdicts favoring plaintiffs and others favoring Bayer, which likely pushed both sides toward negotiated resolution.
By settling without admitting liability, Bayer preserved its ability to continue marketing Yaz and Yasmin worldwide. The company’s public position remains that the products are safe and effective. This creates a somewhat dissonant situation where a manufacturer pays over $2 billion to resolve injury claims while simultaneously insisting nothing was wrong with the product, but this is standard practice in the pharmaceutical industry and should not be interpreted as an admission of guilt or an exoneration.
What the Yasmin Litigation Means Going Forward
The Yaz and Yasmin litigation stands as a significant chapter in pharmaceutical accountability. It demonstrated that contraceptive manufacturers can face massive financial consequences when safety concerns are not adequately communicated, even if the underlying product remains on the market. For consumers, the case reinforced the importance of understanding not just whether a medication works, but how its specific formulation compares to alternatives in terms of risk.
Looking ahead, the resolution of the Canadian class action in 2026 will mark the final chapter of this particular legal saga. Once Saskatchewan approves the settlement and the claims process opens, affected Canadian women will finally have access to compensation, closing out litigation that has spanned well over a decade across two countries. The broader legacy of the Yasmin lawsuits is a heightened awareness, among both prescribers and patients, that newer does not always mean safer when it comes to pharmaceutical formulations.
Conclusion
The Yasmin and Yaz birth control lawsuits resulted in one of the largest pharmaceutical settlements in history, with Bayer paying over $2 billion to resolve more than 19,000 U.S. claims alleging blood clots, strokes, heart attacks, gallbladder disease, and deaths linked to the drospirenone-containing contraceptives. The U.S. litigation is fully closed, and no new claims are being accepted.
In Canada, a proposed CAD $9,050,000 settlement awaits final approval from all three provincial courts, with the Saskatchewan hearing scheduled for February 11, 2026. For anyone affected by these medications, the key takeaway is straightforward: U.S. claimants have no remaining legal avenue, while Canadian class members should watch for updates on the claims process once all courts have approved the settlement. The litigation serves as a lasting reminder that patients should discuss the specific risks and benefits of any contraceptive formulation with their healthcare providers, and that the legal system, however slowly, can provide a mechanism for accountability when those risks are not adequately disclosed.